Mitochon Pharmaceuticals » Logo

Mitochon Pharmaceuticals Announces $1 Million Award From ALS Association for Phase II Clinical Study

August 20, 2026

Mitochon Pharmaceuticals is pleased to announce the receipt of a $1 million Hoffman ALS Clinical Trial Award from the ALS Association. This funding will pave the way for a 24-week sporadic ALS study and expand upon recent clinical studies in Europe showing a quick drop in Neurofilament Light (NfL) in sporadic ALS participants taking MP-101 capsules.

MP-101 is a First-in-Class oral, brain penetrating small molecule that enhances mitochondrial function by correcting high oxidative stress, calcium toxicity, and low energy, while inducing protective factors.

“ALS is a truly insidious disease that typically strikes people in the prime of their life. Appearing rooted in mitochondrial dysfunction, ALS has been top of our priorities for many years, and the findings from Dr. Lan Wei-LaPierre’s, PhD (University Florida) research confirmed that MP-101’s pharmacology matched her theory of calcium toxicity as an early event in motor neuron loss in ALS,” said Dr. John Geisler, PhD CSO/co-founder of Mitochon.

View Full Article
About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.
crosschevron-upchevron-down